This week, the overall grades of eight Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health’s (NASDAQ:GHDX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. GHDX also rates an F in Portfolio Grader’s specific subcategory of Earnings Revisions. The trailing PE Ratio for the stock is 167.80. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.
This week, Acorda Therapeutics (NASDAQ:ACOR) drops from a C to a D rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. The stock price has dropped 14.6% over the past month, worse than the 7.1% increase the Nasdaq has seen over the same period of time. For a full analysis of ACOR stock, visit Portfolio Grader.
The rating of Amarin (NASDAQ:AMRN) slips from a C to a D. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock gets F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of May 22, 2013, 18% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis (NASDAQ:EXEL) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of May 22, 2013, 20.4% of outstanding Exelixis shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader.
Trius Therapeutics (NASDAQ:TSRX) is having a tough week. The company’s rating falls from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
BioSpecifics Technologies (NASDAQ:BSTC) gets weaker ratings this week as last week’s C drops to a D. BioSpecifics Technologies is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The stock gets F’s in Earnings Revisions and Margin Growth. The stock has a trailing PE Ratio of 35.30. For more information, get Portfolio Grader’s complete analysis of BSTC stock.
Discovery Laboratories (NASDAQ:DSCO) earns a D this week, moving down from last week’s grade of C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.
This week, Achillion’s (NASDAQ:ACHN) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of May 22, 2013, 12.8% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.